Compare ARW & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARW | GKOS |
|---|---|---|
| Founded | 1935 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.6B |
| IPO Year | 1994 | 2015 |
| Metric | ARW | GKOS |
|---|---|---|
| Price | $141.40 | $98.99 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $124.33 | ★ $133.07 |
| AVG Volume (30 Days) | 465.5K | ★ 674.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.93 | N/A |
| EPS | ★ 10.93 | N/A |
| Revenue | ★ $30,852,935,000.00 | $507,442,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.51 | $27.46 |
| P/E Ratio | $12.90 | ★ N/A |
| Revenue Growth | 10.49 | ★ 32.33 |
| 52 Week Low | $86.50 | $73.16 |
| 52 Week High | $162.61 | $130.23 |
| Indicator | ARW | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 33.90 |
| Support Level | $120.69 | $81.54 |
| Resistance Level | $161.62 | $102.19 |
| Average True Range (ATR) | 3.84 | 3.51 |
| MACD | -1.63 | -1.86 |
| Stochastic Oscillator | 40.21 | 13.05 |
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the global components business and the global enterprise computing solutions.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.